<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765177</url>
  </required_header>
  <id_info>
    <org_study_id>CLIC-01 Study</org_study_id>
    <nct_id>NCT03765177</nct_id>
  </id_info>
  <brief_title>CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies</brief_title>
  <acronym>CLIC-01</acronym>
  <official_title>Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose an early phase study defined as a phase I/II trial assessing&#xD;
      safety, feasibility and efficacy of CLIC-1901 autologous anti-CD19 Chimeric Antigen Receptor&#xD;
      T cells (CAR-T) cells for participants with relapsed/refractory CD19 positive (CD19+) Acute&#xD;
      Lymphoblastic Leukemia (ALL) and non-Hodgkin's Lymphoma (NHL). The Initial Stage of the study&#xD;
      (n=20 participants) will focus on feasibility and safety while the Extended Stage will&#xD;
      include all participants enrolled in the study (n=additional 40 participants for a total of&#xD;
      60) and will focus on efficacy and safety outcomes. In the proposed trial, we will administer&#xD;
      our CAR-T cell product to these participants as a single infusion. Participants will undergo&#xD;
      (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of&#xD;
      autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have designed a two-stage, single-arm, open-label early phase study to&#xD;
      determine the safety and efficacy of CLIC-1901 cell therapy in patients with CD19+ ALL and&#xD;
      NHL. The primary objective in the initial stage of 20 participants will be to evaluate the&#xD;
      feasibility of our protocol and the safety and tolerability of infusing autologous CLIC-1901&#xD;
      cells into patients with relapsed/refractory CD19+ ALL or NHL. Once 20 participants have been&#xD;
      treated and the treatment is deemed safe, up to 40 more participants will be enrolled in an&#xD;
      extension stage where the primary objective will be overall response rate (defined as&#xD;
      complete or partial response) at 6 months after CLIC-1901 infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants experiencing either Grade 3 or 4 cytokine release syndrome.</measure>
    <time_frame>Within the first 28 days of CAR-T infusion</time_frame>
    <description>Grade 3 or 4 neurological toxicity, other Grade 3 or 4 toxicity (by CTCAE 4.03) or non-relapse related death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with complete (CR) or partial response (PR) to CLIC-1901</measure>
    <time_frame>6 months after CAR-T cell infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Meeting enrollment targets</measure>
    <time_frame>First 20 participants within 12 months and next 40 participants within 2 years of opening the second stage.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>CLIC-1901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single Intravenous infusion of CLIC-1901 will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLIC-1901</intervention_name>
    <description>Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.</description>
    <arm_group_label>CLIC-1901</arm_group_label>
    <other_name>autologous anti-CD19 CAR-T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must have relapsed or refractory CD19+ disease as defined by one of the&#xD;
             following:&#xD;
&#xD;
             a. Relapsed or refractory acute lymphoblastic leukemia as defined by one of the&#xD;
             following: i. Second or greater relapse ii. Any relapse after allogeneic stem cell&#xD;
             transplantation (SCT) iii. Chemorefractory as defined by not achieving CR after 2&#xD;
             cycles of a standard induction chemotherapy or one cycle of salvage therapy b.&#xD;
             Histologically confirmed B-cell non-Hodgkin's lymphoma including diffuse large B-cell&#xD;
             lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma,&#xD;
             or transformed follicular lymphoma with one of the following: i. Second or greater&#xD;
             relapse ii. Any relapse after autologous or allogeneic SCT iii. Chemorefractory as&#xD;
             defined by not achieving CR after 2 cycles of a standard chemotherapy or one cycle of&#xD;
             salvage therapy&#xD;
&#xD;
          2. All eligible participants must have documentation of CD19 tumour expression&#xD;
             demonstrated in tissue biopsy, bone marrow or peripheral blood within the 3 months&#xD;
             prior to study screening.&#xD;
&#xD;
          3. Adequate organ function&#xD;
&#xD;
          4. Participant age: 18 to 75 years.&#xD;
&#xD;
          5. Provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Isolated extra-medullary disease.&#xD;
&#xD;
          2. Participants with concomitant genetic syndrome, such as Fanconi anemia, Kostmann&#xD;
             syndrome, Shwachman syndrome or any other known familial bone marrow failure syndrome.&#xD;
&#xD;
          3. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative&#xD;
             intent and with no evidence of active disease.&#xD;
&#xD;
          4. Prior treatment with any gene therapy product.&#xD;
&#xD;
          5. Participants with polymerase chain reaction (PCR) positive hepatitis B, hepatitis C,&#xD;
             or Human Immunodeficiency Virus (tested within 8 weeks of screening), or any&#xD;
             uncontrolled infection at screening.&#xD;
&#xD;
          6. Presence of active Graft Versus Host Disease requiring systemic therapy.&#xD;
&#xD;
          7. Participants who have undergone allogeneic SCT less than 6 months prior to CLIC-1901&#xD;
             cell infusion or who have undergone donor lymphocyte infusion less than 6 weeks prior&#xD;
             to CLIC-1901 cell infusion.&#xD;
&#xD;
          8. Active Central Nervous System (CNS) involvement by malignancy, defined by CNS-3 per&#xD;
             National Comprehensive Cancer Network guidelines.&#xD;
&#xD;
          9. History of anaphylaxis to gentamicin or its derivatives.&#xD;
&#xD;
         10. Participant has received an investigational agent within the 30 days prior to&#xD;
             enrolment visit.&#xD;
&#xD;
         11. Pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natasha Kekre, MD</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>71064</phone_ext>
    <email>nkekre@toh.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice Black</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>71064</phone_ext>
    <email>aliblack@ohri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Hay, MD</last_name>
      <phone>604-675-8266</phone>
      <email>Kevin.Hay@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Hong Li</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>52496</phone_ext>
      <email>hong.li@bccancer.bc.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Kekre, MD, MPH, FRCP</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>71064</phone_ext>
      <email>nkekre@toh.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alice Black</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>71064</phone_ext>
      <email>aliblack@ohri.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chimeric Antigen Receptor T cells</keyword>
  <keyword>CLIC-1901</keyword>
  <keyword>anti-CD19 CAR-T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

